AbbVie Stock Chart Shows Pocket Pivot Cluster On FDA Breakthrough Therapy

Abbvie stock is a good long-term buy and hold on a “dream-team” pipeline of phase 3 trials.

Summary

  • AbbVie just received breakthrough therapy designation from the FDA for JAK1 inhibitor.
  • The company has a robust pipeline of drugs in phase 3 trials.
  • Over the last 5 years, revenue has been growing by 8.21% per year.
  • AbbVie stock has a bullish pocket pivot cluster with positive Twiggs Money Flow.
  • TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

    Author: Lance Jepsen

    For ethical purposes, I try not to hold any position in any stock I profile on GuerillaStockTrading.com unless specifically stated in the article. Owner of GuerillaStockTrading.com. Seasoned entrepreneur, investor, and writer. I love God, family, country, stock trading, economics, and helping people learn how to trade.

    Leave a Reply

    Sending